The PRIMARA study: A prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice

European Journal of Endocrinology

Volumn 171, Issue 6, 2014, Pages 727-735

  Schwarz, P ⁿ   Body, J J ^a   Cap J ^b   Hofbauer, L C ^c   Farouk, M ^d   Gessl, A ^e   Kuhn, J M ^f   Marcocci, C ^g   Mattin, C ^h   Munoz Torres M ⁱ   Payer, J ^j   Van De Ven, A ^k   Yavropoulou, M ^l   Selby, P ^m  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d AMGEN INC   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^g UNIVERSITY OF PISA   (Italy)

^h AMGEN LTD   (United Kingdom)

ⁱ HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^j UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l AHEPA UNIVERSITY HOSPITAL   (Greece)

^m UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁿ GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET; MAGNESIUM; PHOSPHORUS; NAPHTHALENE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE PAIN; CALCIUM BLOOD LEVEL; CLINICAL PRACTICE; DECREASED APPETITE; DESCRIPTIVE RESEARCH; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NAUSEA; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OBSERVATIONAL STUDY; PARATHYROIDECTOMY; PARESTHESIA; PATIENT SELECTION; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; VERTIGO; VERY ELDERLY; VOMITING; YOUNG ADULT; CLINICAL TRIAL; EUROPE; HYPERPARATHYROIDISM, PRIMARY; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; NAPHTHALENES; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84911965771     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0355     Document Type: Article

References (12)

1. Marcocci C & Cetani F. Primary hyperparathyroidism. New England Journal of Medicine 2011 365 2389-2397. (doi:10.1056/NEJMcp1106636)
2. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C & Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. Journal of Clinical Endocrinology and Metabolism 2014 99 3561-3569. (doi:10.1210/jc.2014-1413)
3. Nemeth EF & Bennett SA. Tricking the parathyroid gland with novel calcimimetic agents. Nephrology, Dialysis, Transplantation 1998 13 1923-1925. (doi:10.1093/ndt/13.8.1923)
4. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. Journal of Pharmacology and Experimental Therapeutics 2004 308 627-635. (doi:10.1124/jpet.103.057273)
5. Coburn JW, Elangovan L, Goodman WG & Frazaõ JM. Calcium-sensing receptor and calcimimetic agents. Kidney International. Supplement 1999 73 S52-S58. (doi:10.1046/j.1523-1755.1999.07303.x)
6. Endres DB & Rude RK. Mineral and bone metabolism. In Tietz Textbook of Clinical Chemistry, edn 3rd, pp 1395-1406. Eds CA Burtis & ER Ashwood, Philadelphia: WB Saunders Company, 1999.
7. Saponaro F, Faggiano A, Grimaldi F, Borretta G, Brandi ML, Minisola S, Frasoldati A, Papini E, Scillitani A, Banti C et al. Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Clinical Endocrinology 2013 79 20-26. (doi:10.1111/cen.12108)
8. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA & Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2005 90 135-141. (doi:10.1210/jc.2004-0842)
9. Shoback DM, Bilezikian JP, Turner SA, McCary LC, GuoMD&Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2003 88 5644-5649. (doi:10.1210/jc.2002-021597)
10. Cetani F, Saponaro F, Banti C, Cianferotti L, Vignali E, Chiavistelli S, Viccica G, Pinchera A & Marcocci C. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. Journal of Endocrinological Investigation 2012 35 655-660. (doi:10.3275/7970)
11. Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2009 94 2766-2772. (doi:10.1210/jc.2008-2640)
12. Cakal E, Cakir E, Dilli A, Colak N, Unsal I, Aslan MS, Karbek B, OzbekM, Kilic M, Delibasi T et al. Parathyroid adenoma screening efficacies of different imaging tools and factors affecting the success rates. Clinical Imaging 2012 36 688-994. (doi:10.1016/j.clinimag.2012.01.038)